Best Practice™: Streamlining the Pathway to Successful Implementation of Gene Therapy in Hemophilia B " A Focus on the Hub and Spoke Model

Target Audience
This educational activity is directed toward hematologists, specialty nurse practitioners/physician assistants, pharmacists, and nurses who manage patients with hemophilia B.

Program Overview
In this online, on-demand webcast, a renowned expert in the management of patients with hemophilia B will discuss the development of gene therapy for treating this disorder. In this educational program, this expert discusses the latest data regarding clinical trials of various gene therapies and the challenges to implementing gene therapy in hemophilia treatment centers (HTCs).

Gene therapy for hemophilia B has the potential to reduce the treatment burden for patients and their care providers by eliminating the need for regular prophylaxis. Certain challenges associated with gene therapy still need to be addressed to ensure widespread therapeutic use, but this treatment offers a promising option for this patient population. HTCs have already been established to ensure multidisciplinary care for patients and to incorporate clinical specialties, emergency departments, and appropriate laboratory facilities. Overall, gene therapy for hemophilia presents a challenge to the existing structure of HTCs and requires enhanced collaboration and information sharing to maximize benefits and minimize risks. A “hub and spoke” model has been proposed to ensure time and expertise for patient counseling, informed consent, and clear demarcation of responsibility for different aspects of the procedure. This educational activity will address the evolving treatment paradigm for hemophilia B, including the role of gene therapy and ways that it may change the way in which hemophilia care is delivered.

This educational activity is an archive of the live virtual webcast held on January 25, 2023.

Learning Objectives
Upon completion of this activity, participants should be better able to:
Identify the role of gene therapy in the treatment paradigm for hemophilia B
Describe models for implementation of gene therapy for hemophilia B into clinical practice
Discuss the role of the multidisciplinary team in the management of patients receiving gene therapy for hemophilia B